KURA Nasdaq· Kura Oncology Inc.
FundamentalsNews digest Peer analysis
KURA Nasdaq· Kura Oncology Inc.
Earnings report Q4 2023

KURA Oncology Reports Strong Revenue Growth in Latest Quarter

Segments of Revenue

KURA Oncology, a clinical-stage biopharmaceutical company, reported impressive revenue growth in the latest quarter. The company's revenue is primarily derived from its small molecule product candidates that target cancer signaling pathways.


KURA Oncology's revenue for the latest quarter showed significant growth compared to the previous year. The company's revenue increased from $139.9 million in the previous year to $165.8 million in the latest quarter, representing a growth of 18.6%. This growth can be attributed to the progress made in the clinical trials of their three product candidates: ziftomenib, tipifarnib, and KO-2806. KURA Oncology's management has emphasized their commitment to realizing the promise of precision medicines for cancer treatment, and their focus on pairing their product candidates with molecular or cellular diagnostics to identify patients most likely to respond to treatment.


While KURA Oncology has shown strong revenue growth, it is important to note that the company is still operating at a net loss. The net loss for the latest quarter was $152.6 million, which is higher than the previous year's net loss of $135.8 million. This indicates that the company's expenses are outpacing its revenue growth. KURA Oncology will need to carefully manage its operating expenses, particularly in research and development and general and administrative areas, to achieve profitability in the future.


KURA Oncology's revenue growth in the latest quarter is noteworthy, as it demonstrates the positive impact of their clinical trials and the potential of their product candidates in the market. Additionally, the company's ownership of global commercial rights to all of its programs and product candidates provides them with significant control over their development and commercialization strategies.


KURA Oncology reported strong revenue growth in the latest quarter, driven by progress in their clinical trials and the potential of their product candidates. However, the company continues to operate at a net loss, indicating the need for careful expense management. Overall, KURA Oncology's focus on precision medicines for cancer treatment and their commitment to pairing their product candidates with diagnostics position them well for future success in the biopharmaceutical industry.

Source documents

Form 10-K  filed on Feb 27, 2024
62 pages scanned

Reference data

Company financials Q4 revenue 0
Analyst estimates Q4 EPS missed by -0.60%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.